Novartis Ag (NVS) Assets (2009 - 2026)
Novartis Ag (NVS) posted Assets of $122.0 billion for Q2 2026, up 9.99% sequentially from $110.9 billion in Q4 2025, and up 16.9% YoY from $104.4 billion in Q2 2025.
Novartis Ag (NVS) Assets (2009 - 2026) Analysis & Trends
Novartis Ag has reported Assets for 18 years, with the latest figure at $122.0 billion in Q2 2026.
- Quarterly Assets rose 16.9% year-over-year to $122.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $122.0 billion (up 16.9% YoY) and the FY2025 annual result came in at $110.9 billion, up 8.51% from the prior year.
- Assets climbed to $122.0 billion in Q2 2026 per NVS's latest filing, from $110.9 billion in the prior quarter.
- Over five years, Assets peaked at $122.9 billion in Q2 2022 and troughed at $97.5 billion in Q2 2024.
- A 5-year average of $109.8 billion and a median of $110.9 billion in 2025 frame the typical range for Assets.
- The sharpest annual moves came in 2023 and 2026: Assets decreased 14.91% in 2023, then gained 16.9% in 2026.
- Over 5 years, Assets stood at $117.5 billion in 2022, then retreated by 14.91% to $99.9 billion in 2023, then grew by 2.3% to $102.2 billion in 2024, then advanced by 8.51% to $110.9 billion in 2025, then grew by 9.99% to $122.0 billion in 2026.
- According to Business Quant data, Assets over the past three periods registered $122.0 billion, $110.9 billion, and $104.4 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 82.83 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 150.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 122.03 Bn |
| Dec 31, 2025 | 110.95 Bn |
| Jun 30, 2025 | 104.40 Bn |
| Dec 31, 2024 | 102.25 Bn |
| Jun 30, 2024 | 97.51 Bn |
| Dec 31, 2023 | 99.95 Bn |
| Jun 30, 2023 | 110.98 Bn |
| Dec 31, 2022 | 117.45 Bn |
| Jun 30, 2022 | 122.91 Bn |
| Dec 31, 2021 | 131.80 Bn |
| Jun 30, 2021 | 124.02 Bn |
| Dec 31, 2020 | 127.78 Bn |
| Jun 30, 2020 | 123.76 Bn |
| Dec 31, 2019 | 118.37 Bn |
| Jun 30, 2019 | 116.29 Bn |
| Dec 31, 2018 | 145.56 Bn |
| Jun 30, 2018 | 142.06 Bn |
| Dec 31, 2017 | 133.08 Bn |
| Dec 31, 2016 | 130.12 Bn |
| Dec 31, 2015 | 131.56 Bn |